Practical Pearls for Diagnosing Disorders of Hyperpigmentation
If you find diagnosing disorders of hyperpigmentation challenging, then this is just for you! I had the privilege of attending the 2023 ODAC Dermatology, Aesthetic, and Surgical Conference to learn about disorders of hyperpigmentation from Dr. Nada Elbuluk. Dr. Elbuluk is an Associate Professor and Director of the Skin of Color Program and Pigmentary Disorders Clinic at the University of Southern …
If you find diagnosing disorders of hyperpigmentation challenging, then this is just for you! I had the privilege of attending the 2023 ODAC Dermatology, Aesthetic, and Surgical Conference to learn about disorders of hyperpigmentation from Dr. Nada Elbuluk. Dr. Elbuluk is an Associate Professor and Director of the Skin of Color Program and Pigmentary Disorders Clinic at the University of Southern … Continue reading "Practical Pearls for Diagnosing Disorders of Hyperpigmentation"
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Iltefat Hamzavi, dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Dr. Hamzavi addresses how to diagnose and treat hypopigmentation, a catch-all for pigmentary conditions where the pigment is not too dark or complete … 
Essence recently posted an article on how to treat hyperpigmentation on melanated skin. What cosmetic ingredients make the most impact in treating hyperpigmentation in darker skin types? What are the challenges that skin of color poses when treating hyperpigmentation?
For expert advice, I reached out to Miami dermatologist Heather Woolery-Lloyd, MD. She will address hyperpigmentation and other … 
Patients with darker skin types are susceptible to developing other pigmentary disorders besides melasma. At SOCU 2022, Dr. Heather Woolery-Lloyd, Director of the Skin of Color Division at the University of Miami Miller School of Medicine, gave a fascinating overview of various pigmentary disorders that can affect patients with skin of color and provided clinical pearls immediately useful in our p … 
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …